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Background: Experts agree that one of the more promising strategies in cancer management is early detection coupled
with early intervention. In this study, we evaluated an early cancer detection strategy of cancer presence based on serum
levels of the cancer-specific transcript variants of ENOX2 in serum coupled with an ENOX2-targeted nutraceutical
preparation of green tea concentrate plus Capsicum (Capsol-T®) as a strategy of Curative Prevention® involving early
detection coupled with early intervention in early stage cancer when in its most susceptible and manageable stages.
Experimental design: One hundred ten (110) subjects were tested for cancer presence using the ONCOblot® Tissue of
Origin 2-D gel/western blot protocol for detection of serum presence of transcript variants of the ENOX2 protein. Subjects
testing positive for ENOX2 received 350 mg of Capsol-T® in capsule form every 4 h including during the night for periods
of at least 3 to 6 months or longer after which they were again tested for ENOX2 presence using the
ONCOblot® Tissue of Origin Cancer Test protocol.
Results: Of the 110 subjects, both male and female, ages 40 to 84, with no evidence of clinical symptoms of cancer, 40%
were positive for ENOX2 presence in the ONCOblot® Tissue of Origin Cancer Test. After completion of 3 to 17 months of
Capsol-T® use, 94% of subjects subsequently tested negative for ENOX2 presence.
Conclusions: Oral Capsol-T® is well tolerated and, for ENOX2 presence in serum in the absence of clinical cancer
symptoms, is consistently effective in reducing the serum ENOX2 levels to below detectable limits.
Keywords: Cancer, Curative prevention®, Prevention trial, Early detection, Early intervention, Green tea concentrate,
Capsol-T®, ONCOblot Tissue of Origin Cancer TestBackground
Cancer is the second leading disease cause of death in
the United States [1]. A group of more than l00 different
and distinctive diseases, cancer may involve any tissue of
the body. Estimates are that there were over l.6 million
cases in 2012 in the United States alone [2]. While vari-
able among different cancers, only a small fraction, per-
haps 25% or less, are currently diagnosed at a localized
stage where curative therapy is effective [3]. Most can-
cers are diagnosed only after the primary tumor has
already metastasized so that chemotherapy is required
for treatment [4]. Hence, early detection is a favored* Correspondence: dj_morre@yahoo.com
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reproduction in any medium, provided the oropportunity to reduce cancer mortality. By detecting
cancer in its very earliest stages, when perhaps only a
small number of cells are present, it is possible that early
intervention will be effective in preventing further devel-
opment of the incipient cancer thereby resulting in what
might be viewed as Curative Prevention® [5].
Thus, despite advances in early detection of major forms
of human cancer (prostate, breast, lung, colon, leukemia,
lymphoma), more often than not, cancers have developed
to a sufficiently late stage at the time of detection to pre-
clude most opportunities for curative therapy [1,3]. The
problem is exacerbated for pancreatic cancer, as an ex-
ample, where clinical symptoms invariably are delayed until
the disease state is well advanced beyond metastatic spread
[1,3]. A need for early detection remains as one of the mostLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Molecular weight and isoelectric point ranges (99
percentile) from ONCOblot data base of ENOX2 transcript
variants for tissues of origin encountered in study
Cancer n Molecular weight Isoelectric point, pH
Bladder 9 63-66 and 42-48 kDa 4.2-5.8 and 4.1-4.8
Blood cell 80 38-48 kDa 3.6-4.5
Breast 355 64-69 kDa 4.2-4.9
Cervical 18 90-100 kDa 4.2-5.4




Melanoma 27 37-41 kDa 4.6-5.3
Mesothelioma 10 59-62 and 38-41 kDa 3.8-4.1 and 4.4-4.6
Non-small cell lung 75 53-56 kDa 4.7-5.3
Ovarian 78 72-90 and 37-47 kDa 3.7-5.0 and 3.7-5.0
Papillary thyroid 5 56-66 and 37-44 kDa 4.5-4.9 and 3.2-3.7
Prostate 79 71-88 kDa 5.1-6.5
Squamous cell 10 54-68 kDa 5.0-5.4
Uterine 9 64-69 and 36-48 kDa 4.2-4.9 and 4.5-5.6
*All three transcript variants or, frequently, only one or the other of the two
higher molecular weight species, may be present.
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treatment and prevention.
Ecto-Nicotinamide Adenine Dinucleotide Oxidase Di-
sulfide-Thiol Exchanger 2 (ENOX2) (GenBank accession
no. AF207881) [6], also known as Tumor-Associated
Nicotinamide Adenine Dinucleotide Oxidase (tNOX), is
ideally suited as a target for early diagnosis of cancer as
well as for early preventive intervention [5,7]. The pro-
teins are expressed on the cell surface of malignancies
and detectable in the serum of patients with cancer [8].
ENOX2 proteins are terminal hydroquinone oxidases
of plasma membrane electron transport. From the
standpoint of early intervention, they are important in
the growth and enlargement of tumor cells [5,9-11].
Our approach, using ENOX2 as a target for both early
detection and for early intervention, is based on these
properties [5,7,9,12,13]. While ENOX2 presence provides
a non-invasive approach to cancer detection, without
methodology to identify cancer site-specific ENOX2
forms, it offered no indication as to cancer type or
location.
The opportunity to simultaneously determine both
cancer presence and cancer site emerged as a result of
2-dimensional gel electrophoretic separations where
western blots with a pan ENOX2 recombinant single
chain variable region (ScFv) antibody carrying an S tag
[14] or linked to alkaline phosphatase was employed for
detection. The antibody cross-reacted with all known
ENOX2 forms from hematological and solid tumors of
human origin but, of itself, did not differentiate among
different kinds of cancers. Analyses using this antibody,
when combined with two-dimensional gel electrophor-
etic separation, revealed specific ENOX2 species subse-
quently identified as transcript variants, each with a
characteristic molecular weight and isoelectric point in-
dicative of a particular form of cancer [14] (Table 1).
ENOX transcript variants of specific molecular weights
and isoelectric points are produced uniquely by patients
with cancer [14]. The proteins are shed into the circula-
tion and have the potential to serve as definitive, non-
invasive and sensitive serum markers for early detection
of both primary and recurrent cancers in at risk popula-
tions with a low incidence of both false positives and
false negatives, as they are molecular signature mole-
cules produced specifically by cancer cells and are absent
from non-cancer cells. The predictive correlation be-
tween ONCOblot findings and actual onset of cancer is
based on observations that a positive ONCOblot indi-
cates the presence of ENOX2 which is a definitive
marker of cancer presence.
Phase I studies with green tea concentrate have shown
that green tea products may be administered safely at oral
doses of up to 5 g/day [15]. Dose limiting toxicities are
primarily associated with the caffeine content [15,16].Therefore, the present study was to determine whether an
oral decaffeinated green tea product might be effective in
early cancer intervention with efficacy based on elimin-
ation or reduction to below the limits of detection of the
cancer-specific ENOX2 proteins from subjects’ sera.
Patients and methods
Eligibility
A total of 110 subjects were enrolled. Subjects were re-
cruited primarily from the Lafayette, Indiana area. Eligible
subjects were males and post-menopausal females or fe-
males following an accepted method of contraception be-
tween the ages of 40 and 84 years, having no clinical
evidence or history of cancer, and a body mass index be-
tween 18-35 kg/m2. All subjects gave their written informed
consent and agreed to refrain from taking commercially
available green tea supplements during the trial.
Subjects were excluded from participation if any of the
following applied:
 Sexually active pre-menopausal female not using
contraception
 Current diagnosis of active cancer other than
superficial basal cell carcinoma (any stage)
 Less than 5 years post cancer with no evidence of
disease
 Known HIV infection
 Subject had a bleeding or clotting disorder
 Participation in another clinical study involving the
use of an investigational drug or product within the
past 20 days
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No further data was collected if the following occurred
 The investigator decided to discontinue the study in
the best medical interest of the subject (e.g., due to
noncompliance, an adverse event, or a change in
medical status)
 The subject requested withdrawal from the study
 The subject died
 The subject never received product
 The subject never met study entry criteria
 If a subject’s participation in the study was
terminated prematurely, the primary reason for
withdrawal was recorded and the end of study
assessments were obtained, if possible.
Product characteristics
The source of food grade green tea concentrate was a
synergistic mixture of decaffeinated green tea plus Cap-
sicum powder marketed under the trade name of
Capsol-T® and provided as clear, oval-shaped 350 mg gel
capsules. The capsules contained food grade decaffein-
ated green tea powder and food grade red pepper pow-
der (Capsicum) in a ratio of 25:1 (green tea:Capsicum).
The caffeine content of the 350 mg Capsol-T® product
was 0.472% (1.65 mg caffeine), as determined by high
performance liquid chromatography. The daily amount
of caffeine for each subject was approximately 10 mg.
The average cup of coffee contains between 90 and
150 mg of caffeine. A daily dose of Capsol-T® distributed
over a 24 h period contained less than 10% of the caf-
feine of a single cup of coffee.
The vitamin K contained in natural green tea can re-
duce effectiveness of blood thinning medications, such
as warfarin. The decaffeination process for Capsol-T®
removes the vitamin K naturally present in green tea, to
below levels found, for example, in lettuce.
The Capsicum powder component of Capsol-T® is
from a relatively mild pepper (guajillo, a red pepper
similar to bell peppers). This variety of pepper was spe-
cifically chosen to avoid the potential side effects and
risks associated with capsaicin, a chemical ingredient
found in “hot” peppers. The capsaicin content in the
Capsol-T® pepper component is low or undetectable
either by taste (measured as 0 scoville units; scoville
units indicate the amount of capsaicin, or spicy heat) or
by high performance liquid chromatographic methods,
using the concentrated starting material blended with
the green tea.
The Capsol-T® was prepared to meet Good Manufac-
turing Practice (GMP) requirements and was provided
by Stratum Nutrition, a division of Novus International,
St. Charles, Missouri (TeaFense).Study design
The study design was that of a non-randomized, open-
label and IRB-approved Phase II trial of serum ENOX2
early detection followed by Capsol-T® intervention to re-
duce ENOX2 levels to below levels of detection in the
ONCOblot® Tissue of Origin Cancer Test (ONCOblot®)
protocol used for early detection. Here, we report on the
first 110 subjects who satisfied all inclusion and exclu-
sion criteria.
All study subjects were evaluated for serum presence
by the standard ONCOblot® test [14]. Study subjects
with serum presence of ENOX2 transcription variants
were provided with Capsol-T® and instructed to con-
sume one 350 mg Capsol-T® capsule 6 times daily, once
every 3 to 5 h even during the night with a liquid of
their choice other than green tea and with or without
food before or after supplement consumption. They
were instructed that if they missed a dose of the product,
they should take the dose as soon as possible thereafter.
Missed doses were recorded in the subject’s diary.
Subjects consumed the capsules daily, as instructed,
for up to a 6 month period or longer, beginning at the
baseline visit and continuing until their last visit and
ONCOblot® retest.
Evaluation during study
At the screening visit, demographic data were collected
which included the following: age, gender, height, body
weight, and calculated BMI (kg/m2).
During the screening period, information regarding
the subject’s medical history including but not limited
to, prior medication and contraception use, alcohol con-
sumption, and smoking history to assess those charac-
teristics that may affect efficacy/safety or study variables,
was recorded.
Treatment efficacy was based on ablation of ENOX2 pro-
tein in sera of the treatment group with efficacy evaluated
at 6 to 9 months compared to baseline with an optional
ONCOblot® test at 3 to 5 months. Retesting was delayed
for more than a year in 5 patients and 12 were not retested.
Serum samples were analyzed for the presence of
ENOX2 transcript variants using the ONCOblot® test
which uses 2-D gel/western blot analysis. Based on pre-
vious work, the distinct patterns of ENOX2 isoforms
with characteristic molecular weights and isoelectric
points (pH) from patients within this study are summa-
rized in Table 1.
Subject compliance was monitored through review of
subject diaries at Visit 2 (3 months) and at Visit 3 (6 to
9 months).
Subjects agreed to refrain from taking commercially
available green tea supplements during the trial. Subjects
also agreed not to take any of the medications having
potential interactions with components of Capsol-T®.
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during the study.
Adverse event assessment
Following protocol guidelines, any adverse events were
assessed and recorded regularly including any unfavor-
able or unintended sign, such as hematological and other
laboratory abnormalities, symptoms temporarily associ-
ated with the use of the product, whether or not consid-
ered related to the product, including (but not limited
to) those events resulting from use as stipulated in the
protocol that required intervention by a health care pro-
fessional, including withdrawal of product, reduced
product administration, or significant additional con-
comitant therapy.
Results
All 110 patients were evaluated for presence of ENOX2
transcript variants (Table 1). Their median age was
60 years (range 40-84 years) (Table 2). Forty-three pa-
tients were men. None of the patients were previously
diagnosed with cancer.
Of the 110 subjects, 66 were negative in the ONCO-
blot® Tissue of Origin Cancer Test, indicative of the ab-
sence of ENOX2 transcript variants or a level of ENOX2
transcript variants below the level of detection in the test
(Table 3). Of the 44 subjects with positive ONCOblot®
Tissue of Origin Cancer Tests, i.e., with evidence for an
ENOX2 transcript variant, non-small cell lung (20%),
breast (16%), colorectal (9%), blood cell, ovarian, pros-
tate and cervical all at 7% each were among the most
prevalent based on molecular weight and isoelectric
point characteristics compared to data base values from
patients with clinically diagnosed cancers (Table 1). Also
represented were malignant mesothelioma, squamous
cell, cervical, uterine and papillary thyroid cancers.
The 44 subjects presenting with an ONCOblot® Tissue
of Origin Test with evidence for an ENOX2 transcript
variant, were provided with successive 3 month supplies
of Capsol-T® and retested at the interval shown. A total
of 12 subjects failed to return for a retest (Table 2). Of
the 32 subjects that did return for a retest, 2 (4%)Table 2 Patient characteristics
Characteristics Number
Total number of patients 110
Number of patients evaluated for toxicity 32
Number of patients evaluated for response to
therapy
32
Median (range) age, years 60 (40–84)
Gender: male number 43
Median (range) time from diagnosis to negative
ONCOblot® retest (months)
8 (3–17)remained positive for ENOX2 splice variant presence.
Six patients, when retested at 3 to 5 months, were nega-
tive. An additional 16 subjects had negative ONCOblot®
Tissue of Origin Tests when retested between 6 and
9 months after entering the study. For 6 subjects, where
retesting was delayed until 12 to 17 months, the ONCO-
blot® Tissue of Origin Test was negative as was one pa-
tient that was not retested until 2 years after entering
the study. With the exception of the latter patients the
mean interval between admission into the study and the
return of a negative ONCOblot® Tissue of Origin Test
was 8 ± 4 months.
Sera from individual patients with various forms of
cancer were analyzed by 2-D gel electrophoresis and im-
munoblotting to assign each of the ENOX2 isoforms to
a cancer of a particular tissue of origin (Table 1). Sera of
breast cancer patients contained only the 64-69 kDa
ENOX2, isoelectric point pH 4.2-4.9. Sera from cervical
cancer patients contained a 90-100 kDa ENOX2 tran-
script variant, pH 4.2-5.4. Sera from patients with pros-
tate cancer contained 71 to 88 kDa ENOX2 transcript
variants of isoelectric point, pH 5.1-6.5. Sera from pa-
tients with non-small cell lung carcinoma contained a 53
to 56 kDa ENOX2 transcript variant, pH 4.7-5.3 while
sera from ovarian cancer patients contained two ENOX2
transcript variants of 72 to 90 kDa and 37 to 47 kDa,
both pH 3.7 to 5.0. Sera of colorectal cancer patients
contained at least two of three possible ENOX2 tran-
script variants of 80 to 96 kDa, pH 4.5 to 5.3, or 50 to
60 kDa, pH 4.2 to 5.1 or 33 to 46 kDa, pH 3.8-5.2. A 38
to 48 kDa ENOX2 transcript variant of low isoelectric
point pH 3.6 to 4.5 was characteristic of leukemias,
lymphomas and other blood cell cancers. Sera of pa-
tients with malignant melanoma contained an ENOX2
transcript variant of 37 to 41 kDa, pH 4.6 to 5.3. Mo-
lecular weights and isoelectric points of other ENOX2
transcript variants associated with particular kinds of
cancer encountered in the study (bladder, cervical,
mesothelioma, papillary thyroid, squamous cell and uter-
ine) are provided in Table 1. Representative paired
ENOX2-positive ONCOblots with the initial blot on the
left and the post-Capsol-T® ONCOblots on the right are
illustrated in Figure 1.
One patient, whose ONCoblot Tissue of Origin Can-
cer Test showed an ENOx2 protein indicative of non-
small cell lung cancer, elected not to take the Capsol-T®,
withdrew from the study and was clinically diagnosed
with non-small cell lung cancer 36 months later. An-
other patient whose original ONCOblot® Tissue of Ori-
gin Test indicated leukemia/lymphoma withdrew from
the study, elected not to take the Capsol-T®, and was
clinically diagnosed with lymphoma 10 months later.
Of the two patients testing positive following Capsol-T
intervention, records ruled out non-compliance as an
Table 3 Baseline early cancer presence and result
ENOX2 present Transcript variant Retest Post intervention
MW pH months MW pH
1. 57 F 55 4.2 Colorectal 14 Negative
38 4.0
2. 64 F Negative
3. 45 F Negative
4. 51 F Negative
5. 71 M 58 4.0 Mesothelioma (Mesothelium) 9 Negative
40 3.9
6. 58 M 54 5.1 Non-small cell lung 7 Negative
7. 59 F 75 4.8 Ovarian 8 Negative
40 4.6
8. 61 F Negative
9. 81 F Negative
10. 55 F Negative
11. 68 F 64 4.2 Breast 7 Negative
12. 52 M 54 5.0 Non-small cell lung 12 Negative
13. 45 F Negative
14. 46 F Negative
15. 73 F 80 4.5 Ovarian 7 Negative
38 4.1
16. 54 F Negative
17. 63 F Negative
18. 75 F 66 4.2 Breast 6 Negative
19. 53 M Negative
20. 67 F 80 4.6 Colorectal 7 Negative
52 5.1
21. 73 M Negative
22. 70 M Negative
23. 61 F Negative
24. 50 F 54 5.2 Non-small cell lung 22 54 5.2
25. 54 F 64 4.2 Breast 8 Negative
26. 84 M 54 5.2 Non-small cell lung 5 Negative
27. 59 F Negative
28. 74 M 56 4.8 Non-small cell Lung 4 Negative
29. 64 F 58 4.5 Colorectal No retest
40 4.4
30. 61 M Negative
31. 52 F Negative
32. 83 M Negative
33. 75 M Negative
34. 51 F 43 3.8 Blood cell 17 Negative
35. 71 F Negative
36. 65 M Negative
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Table 3 Baseline early cancer presence and result (Continued)
37. 50 F Negative
38. 47 M 39 4.4 Blood cell 12 Negative
39. 54 F 50 5.1 Colorectal 12 Negative
38 3.8
40. 71 M 54 5.1 Non-small cell lung No retest
41. 79 M 120 4.5 Not in data base 7 Negative
34 5.2
42. 75 M Negative
43. 59 M 60 5.1 Squamous cell 7 Negative
44. 52 F Negative
45. 63 F 35 4.0 Generic ENOX2 14 64 5.1
46. 60 F Negative
47. 58 F Negative
48. 61 F 68 4.4 Breast No retest
49. 52 F 42 3.9 Blood cell No retest
50. 76 M Negative
51. 54 F Negative
52. 54 F Negative
53. 63 F 55 5.0 Non-small cell lung No retest
54. 52 F Negative
55. 56 F Negative
56. 49 F 92 4.6 Cervical 3 Negative
57. 54 F Negative
58. 58 M 88 5.1 Prostate No retest
59. 68 F 68 4.2 Breast 8 Negative
60. 49 F Negative
61. 50 F Negative
62. 64 F Negative
63. 62 M 33 4.2 Generic ENOX2 9 Negative
64. 50 F Negative
65. 50 M 40 5.0 Melanoma No retest
66. 72 F 64 4.6 Breast No retest
67. 49 F Negative
68. 50 F Negative
69. 54 F 54 5.0 Non-small cell lung No retest
70. 73 M Negative
71. 49 F Negative
72. 81 F Negative
73. 47 F 75 4.1 Ovarian No retest
46 4.0
74. 48 M 80 4.2 Not in data base 9 Negative
75. 56 F Negative
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Table 3 Baseline early cancer presence and result (Continued)
76. 46 M Negative
77. 54 F 67 4.5 Uterine 3 Negative
39 4.9
78. 54 F Negative
79. 65 M Negative
80. 55 M 68 4.0 Not in data base 9 Negative
81. 60 M 83 5.7 Prostate 12 Negative
82. 80 F Negative
83. 58 M 71 5.5 Prostate 12 Negative
84. 83 M Negative
85. 53 M Negative
86. 78 F Negative
87. 40 F 90 5.4 Cervical 6 Negative
88. 64 M Negative
89. 56 M Negative
90. 62 F 65 4.2 Breast No retest
91. 52 F Negative
92. 57 F 58 4.6 Papillary thyroid 7 Negative
44 3.7
93. 52 F Negative
94. 67 M Negative
95. 70 M Negative
96. 46 M 68 5.1 Squamous cell 24 Negative
97. 52 F Negative
98. 56 F Negative
99. 53 M Negative
100. 59 M 54 4.8 Non-small cell lung No retest
101. 66 M Negative
102. 70 F Negative
103. 59 M Negative
104. 77 F 92 5.1 Cervical 4 Negative
105. 68 M Negative
106. 62 M Negative
107. 58 F Negative
108. 78 F 66 4.6 Bladder 3 Negative
44 4.6
109. 62 M Negative
110. 65 M Negative
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patient’s initial serum sample revealed that the patient’s cir-
culating ENOX2 was resistant to Capsol-T which occurs
occasionally. With patient 45, a retest after 36 months, ap-
proximately one year following formal closure of the study,
returned a negative result.Patient 45 was of interest in that the initial ONCOblot®
Tissue of Origin Test result was a 35 kDa, pH 4.0 fully
processed, generic ENOX2. Retesting after 14 months now
revealed a 64 kDa pH 5.1 transcript variant indicative of
breast cancer. Generic ENOX2 is frequently associated with
early stage cancer, is not organ site specific and exhibits a
Figure 1 2-D gel-western blot images of patients 7 (ovarian cancer), 26 (non-small cell lung cancer), 104 (cervical cancer), and 108
(bladder cancer). Isoelectric focusing was in the first dimension, pH range 3 to 5 shown, with sodium dodecyl sulfate gel electrophoresis in the
second dimension with comparisons to a standard reference α-fetuin (R). The initial blots are on the left for each pair where the tissue of
origin-specific transcript variant proteins are indicated by arrows. Sera analyzed from the same patients post Capsol-T® intervention are shown on
the right. R = α-fetuin reference protein common to all non-cancer and cancer patient sera. Molecular weights, isoelectric points and patient
information are provided in Table 3.
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pH 3.8 ± 0.1) which is always less than that of the organ site
specific transcript variants. The low molecular weight
is suggestive of nearly complete processing with the pro-
duction of a limit, protease resistant, fragment. Such a limit
fragment is common to most tissues of origin as indicated
from ENOX2 fragments produced by different tissues
of transgenic mice transfected with human ENOX2
cDNA [17].
Three patients, numbers 41, 74 and 80, presented with
immunoreactive ENOX2 transcript variants not in the
data base but tested negative 7 or 9 months later after
taking the Capsol-T®.
Available data in humans from Capsol-T studies have
so far indicated no clear adverse event profile for
Capsol-T®. Polyphenols of green tea do block the action
of the drug bortezomib (Velcade®) [18].
Discussion
The percentage of subjects with a positive ONCOblot®
Tissue of Origin Test result for ENOX2 protein presence
of 40% was not unexpected in view of evidence that ap-
proximately one-half of all males and one-third of all fe-
males within the population of the United States will
contract cancer between the ages of 60 and 85. Interest-
ingly, among the ENOX2 transcript variants with thegreatest incidence, 16 and 20%, were those characteristic
of breast and non-small cell lung cancer, two cancers
generally regarded as characterized by extended latency
periods perhaps even as long as 20 years [5,19].
Unlike most published cancer markers, cancer-specific
ENOX2 variants are not simply present as elevated levels
of a serum constituent present in lesser amounts in the
absence of cancer. The cancer-specific ENOX2 tran-
script variants result from cancer-specific expression of
alternatively spliced mRNAs [10,11]. Neither the splice
variant mRNAs nor the ENOX2 isoform proteins are
present in detectable levels in non-cancer cells or in sera
of subjects without cancer [5,7,14]. Multiple transcripts
within a single tissue of origin may be attributed to dif-
ferent alternative splicing events as well or to transcrip-
tion from independent promoters as shown for the
glutamate transporter EAAC1 [20].
There was insufficient evidence to correlate positive
ONCOblots with hereditary familial cancer or to evalu-
ate the non-predictive power of the test. Follow up of
those patients remaining in the study is ongoing.
Based on lower limits of detection on ONCOblots, we
estimate detection of < 100 femtomoles of ENOX2 equiva-
lent to 6 × 1010 ENOX2 molecules in 20 μl of serum
requiring an estimated 2 × 106 cancer cells in the body
to generate, and equivalent to a 0.8 mm diameter
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about 10 microns, one cm3 of cancer would contain
about 10 billion cells. While estimates vary, 7 mm diam-
eter breast cancers were found about 50% of the time by
mammography whereas tumors larger than 32 mm were
required to be detected 100% of the time [21]. By compari-
son, a 32 mm tumor would contain approximately 1.3
trillion cells.
The most potent inhibitors of ENOX2 are EGCg [22]
and the vanilloid, capsaicin [23]. The effect of EGCg on
growth inhibition of HeLa cells and on inhibition of the en-
zymatic activity of ENOX2 was found to be synergized in
the presence of other inactive green tea catechins such as
epicatechin (EC). This suggested that green tea extracts
might be a superior alternative to single agent EGCg prepa-
rations [24]. Additionally, a product containing a synergistic
combination of decaffeinated green tea and a commercially
available vanilloid-containing Capsicum preparation at a ra-
tio of 25:1, resulted in a 100 fold increase in killing of cul-
tured cancer cell lines compared to green tea alone [25].
Subsequent studies with HeLa cells indicated that one
250 mg capsule of the synergistic green tea-Capsicum mix-
ture every 4 h was equivalent to drinking 16 cups of green
tea every 4 h. The need for 1 capsule every 4 h is substanti-
ated by pharmacokinetic information [26] and the know-
ledge that the inhibition of ENOX2 by both EGCg and by
vanilloids is reversible [22]. In order to have therapeutic ef-
ficacy in selective killing of cancer cells, the catechins must
be present in the culture medium at a level of about 100
nM and to inhibit ENOX2 continuously at that level for a
period of 48 to 72 h [22]. If EGCg, for example, is removed
and replaced by EGCg-free media, even after 8 h, the cul-
tured cancer cells resume normal rates of growth. Similarly,
normal rates of growth are resumed as EGCg is cleared
from the culture medium and/or metabolized. In cell cul-
ture, the EGCg may not survive in the media for more than
a few h at nanomolar concentrations. The cancer cells
in vitro must be inhibited from growing for at least 48 and
perhaps up to 72 h in order for apoptosis to be induced by
EGCg in a majority of the cancer cells present.
Feasibility of an efficacious dosing schedule is indi-
cated from studies with rats [26]. The results from the
animal study are consistent with epidemiological studies
in humans and animal experiments where benefit in pre-
vention of cancer has been ascribed to drinking at least
10 cups of green tea per day without adverse effects
[27,28]. Green tea polyphenols are absorbed after oral
administration and reach their highest plasma levels
after about l to 2 h after dosing both in rats [26,29,30]
and in humans [31]. In the rat, the levels of EGCg
reached a concentration of 12.3 nmoles/ml in plasma
(12.3 μmolar) 60 min after a single oral administration
of 500 mg/kg body weight of EGCg [32], which is more
than l00 times the effective dose to stop the growth oftumor cells. The studies by Yang [33] show that the con-
centration of EGCg in the blood after 2-3 cups of green
tea reached a maximum of about 0.6 μM.
In human studies of ingested catechins, 0.2% of the
ingested EGCg and 0.2% to l.3% of ingested (-)-epigallo-
catechin (EGC) were found in plasma 90 min after
ingestion [34]. Van het Hof et al. [35] determined the
half-life for plasma levels of individuals drinking 8 cups
of tea per day for 3 days to be 4.8 h for green tea and
6.9 h for black tea. After ingestion of green tea by hu-
man volunteers, Cmax values were observed 1.4 to 2.4 h
after ingestion with a half-life of 5 to 5.5 h [36]. These
observations provided the rational basis for dosing at
regular intervals of 4 h with the Capsol-T product.
Tea catechins, especially EGCg, in combination with
Capsicum have been characterized as specific ENOX2
inhibitors inducing apoptotic cell death in cancer but
not in non-cancer cell lines [22,37,38]. Safety and effi-
cacy are well documented [39]. Safety has been the sub-
ject of a series of reports dealing with genotoxic, acute,
dermal, sub-chronic short-term, teratogenic and repro-
ductive assays e.g., [39-41]. Capsol-T® is both caffeine-
and vitamin K-free and free of herbicide, pesticide and/
or heavy metal residues. Its principal catechin constitu-
ent, EGCg, was affirmed to be generally recognized as
safe by an independent review panel [42].
As the 2-D-western blot protocol detects cancer early,
well in advance of clinical symptoms, the opportunity to
combine early detection with early intervention as a po-
tentially Curative Prevention® strategy for cancer by
eliminating the disease in its very earliest stages is
unique. The approach to early intervention is based on
previous work in cell culture models showing that
ENOX2 proteins are required to support the unregulated
growth that typifies cancer cells [7]. If the growth func-
tion of ENOX2 is blocked for 48 to 72 h, the cancer cells
cannot enlarge following division, cannot pass the
checkpoint in G1 that monitors cell size and eventually
undergo programmed cell death (apoptosis) [22,37,43].
As an early intervention strategy targeted to ENOX2,
the herbal mixture of green tea and a powdered effica-
cious source of chili peppers (Capsicum species) with
levels of capsaicin sufficiently low so as to not cause dis-
comfort (Capsol-T®), emerges as being effective in redu-
cing ENOX2 levels below the limits of detection in
greater than 90% of the subjects thus far evaluated when
combined with early detection based on ONCOblot®
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